Dover Free cash flow decreased by 73.1% to $131.19M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.0%, from $109.28M to $131.19M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 4.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $218.10M | $303.40M | $276.97M | -$26.70M | $128.58M | $199.16M | $293.60M | $192.91M | $155.18M | $345.78M | $459.08M | $126.54M | $167.84M | $240.87M | $385.05M | $109.28M | $151.41M | $370.10M | $486.96M | $131.19M |
| QoQ Change | — | +39.1% | -8.7% | -109.6% | +581.6% | +54.9% | +47.4% | -34.3% | -19.6% | +122.8% | +32.8% | -72.4% | +32.6% | +43.5% | +59.9% | -71.6% | +38.5% | +144.4% | +31.6% | -73.1% |
| YoY Change | — | — | — | — | -41.0% | -34.4% | +6.0% | +822.6% | +20.7% | +73.6% | +56.4% | -34.4% | +8.2% | -30.3% | -16.1% | -13.6% | -9.8% | +53.6% | +26.5% | +20.0% |